In a mouse model of ALS (SOD1G93A transgenic mice), the selective inhibitors of ASK1 K811 and K812 developed by the Ichijo group significantly extended the life span of these animals [79], thus demonstrating that ASK1 inhibition holds a considerable therapeutic potential for the treatment of neurodegenerative diseases and for the prevention of cognitive disorders. Here, MAP3K5 is linked to neurodegenerative disease.